Home › Funds › STEMPOINT CAPITAL LP › CCCC
STEMPOINT CAPITAL LP position in CCCC
C4 THERAPEUTICS INC · Health Care
STEMPOINT CAPITAL LP reported holding 3,293,376 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.0M, representing 2.20% of its reported portfolio and ranking #16 among its reported holdings. STEMPOINT CAPITAL LP has disclosed CCCC holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How STEMPOINT CAPITAL LP's CCCC position evolved
STEMPOINT CAPITAL LP first disclosed a stake in CCCC in Q1 2026 at 453,236 shares (US$1.2M). The position peaked in Q3 2026 at 3,293,376 shares, worth US$11.0M. Across 3 filings, STEMPOINT CAPITAL LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,293,376 shares valued at US$11.0M — an increase of 2,769,728 shares quarter over quarter.. Notable position changes include a 529% increase in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 453.24K | $1.19M | New |
| Q2 2026 | 523.65K | $2.45M | Add |
| Q3 2026 | 3.29M | $10.97M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$23.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.00M sh · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $23.88M · Q3 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M sh · $11.50M · Q3 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- HighVista Strategies LLC 873.28K sh · $2.91M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 577.53K sh · $1.92M · Q3 2026
- Squadron Capital Management LLC 400.00K sh · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on STEMPOINT CAPITAL LP
FAQ
How long has STEMPOINT CAPITAL LP held CCCC?
STEMPOINT CAPITAL LP has disclosed CCCC holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is STEMPOINT CAPITAL LP's current position in CCCC?
As of Q3 2026, STEMPOINT CAPITAL LP holds 3.29M shares of CCCC (C4 THERAPEUTICS INC), valued at $10.97M, representing 2.20% of its reported portfolio and ranking #16.
Has STEMPOINT CAPITAL LP been buying or selling CCCC?
In the latest 13F filing (Q3 2026), STEMPOINT CAPITAL LP increased its position in CCCC. The position peaked in Q3 2026 at 3.29M shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.